Rexahn Pharmaceuticals’ (RNN) “Buy” Rating Reaffirmed at HC Wainwright
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Monday. They currently have a $19.50 price target on the stock.
RNN has been the topic of several other reports. ValuEngine upgraded shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday. Ifs Securities reiterated an “outperform” rating on shares of Rexahn Pharmaceuticals in a research report on Monday, August 7th. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Wednesday, October 4th. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $13.00 target price on shares of Rexahn Pharmaceuticals in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Rexahn Pharmaceuticals has an average rating of “Buy” and a consensus target price of $13.75.
Rexahn Pharmaceuticals (NYSEMKT RNN) remained flat at $$1.93 during trading on Monday. The company’s stock had a trading volume of 137,955 shares, compared to its average volume of 625,748. Rexahn Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $7.10.
TRADEMARK VIOLATION WARNING: “Rexahn Pharmaceuticals’ (RNN) “Buy” Rating Reaffirmed at HC Wainwright” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/rexahn-pharmaceuticals-rnn-buy-rating-reaffirmed-at-hc-wainwright/1683264.html.
Several hedge funds and other institutional investors have recently made changes to their positions in RNN. Sabby Management LLC acquired a new stake in Rexahn Pharmaceuticals in the 2nd quarter worth approximately $706,000. Susquehanna International Group LLP acquired a new stake in Rexahn Pharmaceuticals in the 2nd quarter worth approximately $2,905,000. Finally, Renaissance Technologies LLC lifted its holdings in Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after purchasing an additional 862,000 shares during the last quarter.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.